In a recent report, it was suggested that NVIDIA has one customer that contributes to a significant portion of its revenue, with Microsoft being the likely candidate.
Though Nvidia has been the most direct beneficiary of the rise of AI, buying this under-the-radar exchange-traded fund (ETF) would allow investors to gain AI exposure without single-stock risk.
U.S. Rep. Earl Blumenauer questions FDA oversight of Elon Musk's Neuralink. Recent reports reveal FDA concerns about quality control at Neuralink's facilities, raising doubts about human trials. Blumenauer urges FDA action, citing past violations and rushed experiments.
Recent FDA inspection uncovers quality control issues in Neuralink's animal experiments. Senior expert flags a 'lack of attention to detail,' emphasizing the need for vigilance as Neuralink advances to human trials for brain implants.
The U.S. Small Business Administration (SBA) is set to channel billions into venture capital funds, reshaping the Small Business Investment Company (SBIC) program.
Insilico Medicine, a biotechnology company based in Hong Kong, has initiated a 12-week Phase 2 clinical trial for the first-ever drug created by artificial intelligence, INS018_055 targeting idiopathic pulmonary fibrosis (IPF), a type of chronic lung disease.
